Aarkstore - Acute Heart Failure - Pipeline Review, H1 2015

Aarkstore Enterprise Aarkstore Enterprise

Description

Aarkstore.com announces, The Latest market research report is available in its vast collection "Acute Heart Failure - Pipeline Review, H1 2015"
For more details : http://goo.gl/qxDh0d

Informations

• Publié par: Shubhangi
• Publié le: 03 avril 2015
• Nombre de lectures: 1
• Langue: English

Extrait

Aarkstore Enterprise

Aarkstore - Acute Heart Failure - Pipeline Review, H1 2015

Browse Full Report @

http://www.aarkstore.com/pharmaceuticals-healthcare/101278/acute-heart-failure-pipeline-review-h1-2015

Summary

Published:78 PagesJan 2015|

PDF :6000$ 2000 | Site Licence: $ 4000 | Enterprise Wide Licence : $

Global Markets Directs, Acute Heart Failure - Pipeline Review, H1 2015, provides an overview of the Acute Heart Failures therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Heart Failure and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in- class and best-in-class products.

Aarkstore Enterprise

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Heart Failure and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acute Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acute Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Heart Failure - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Order full Report with TOC and Sample page visit: http://www.aarkstore.com/pharmaceuticals-healthcare/101278/acute-heart-failure-pipeline-review-h1-2015

Aarkstore Enterprise

Table of Contents:

Introduction 6

Global Markets Direct Report Coverage 6

Acute Heart Failure Overview 7

Therapeutics Development 8

Pipeline Products for Acute Heart Failure - Overview 8

Pipeline Products for Acute Heart Failure - Comparative Analysis 9

Acute Heart Failure - Therapeutics under Development by Companies 10

Acute Heart Failure - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Acute Heart Failure - Products under Development by Companies 15

Acute Heart Failure - Companies Involved in Therapeutics Development 16

Amgen Inc. 16

Anexon, Inc. 17

Angion Biomedica Corp. 18

Bayer AG 19

Lee's Pharmaceutical Holdings Limited 20

Novartis AG 21

Nyken BV 22

Ono Pharmaceutical Co., Ltd. 23

PhaseBio Pharmaceuticals, Inc. 24

Aarkstore Enterprise

Trevena, Inc. 25

Acute Heart Failure - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

ANG-4011 - Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

ANX-042 - Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

BR-5489 - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

cenderitide - Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Aarkstore Enterprise

istaroxime - Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

NYK-1112 - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

omecamtiv mecarbil - Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

ONO-4232 - Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

PB-1046 - Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

serelaxin - Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Aarkstore Enterprise

TRV-027 - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

TRV-120023 - Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

ularitide - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Acute Heart Failure - Recent Pipeline Updates 56

Acute Heart Failure - Dormant Projects 68

Acute Heart Failure - Discontinued Products 69

Acute Heart Failure - Product Development Milestones 70

Featured News & Press Releases 70

Oct 16, 2014: Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide 70

Oct 09, 2014: Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation 70

Aug 05, 2014: Trevena Granted Key U.S. Method of Use Patent for TRV027 71

May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure 72

May 19, 2014: Trevena Highlights Phase 2b-BLAST AHF Trial for TRV027 at the European Society of Cardiology Heart Failure 2014 Meeting 72

Aarkstore Enterprise

May 16, 2014: FDA issues Complete Response Letter for RLX030 for acute heart failure 73

Mar 27, 2014: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome 74

Mar 25, 2014: FDA Staff Says Novartis Serelaxin Shouldnt Be Approved 74

Jan 24, 2014: Novartis Europharm's Reasanz Receives CHMP Negative Opinion 75

Jan 24, 2014: Novartis to request re-examination of serelaxin in acute heart failure for conditional marketing authorization in EU 76

Appendix 77

Methodology 77

Coverage 77

Secondary Research 77

Primary Research 77

Expert Panel Validation 77

Contact Us 78

Disclaimer 78

List Of Tables

Number of Products under Development for Acute Heart Failure, H1 2015 8

Number of Products under Development for Acute Heart Failure - Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Acute Heart Failure - Pipeline by Amgen Inc., H1 2015 16

Acute Heart Failure - Pipeline by Anexon, Inc., H1 2015 17

Aarkstore Enterprise

Acute Heart Failure - Pipeline by Angion Biomedica Corp., H1 2015 18

Acute Heart Failure - Pipeline by Bayer AG, H1 2015 19

Acute Heart Failure - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 20

Acute Heart Failure - Pipeline by Novartis AG, H1 2015 21

Acute Heart Failure - Pipeline by Nyken BV, H1 2015 22

Acute Heart Failure - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 23

Acute Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015 24

Acute Heart Failure - Pipeline by Trevena, Inc., H1 2015 25

Assessment by Monotherapy Products, H1 2015 26

Number of Products by Stage and Target, H1 2015 28

Number of Products by Stage and Mechanism of Action, H1 2015 30

Number of Products by Stage and Route of Administration, H1 2015 32

Number of Products by Stage and Molecule Type, H1 2015 34

Acute Heart Failure Therapeutics - Recent Pipeline Updates, H1 2015 56

Acute Heart Failure - Dormant Projects, H1 2015 68

Acute Heart Failure - Discontinued Products, H1 2015 69

List Of Figures

Number of Products under Development for Acute Heart Failure, H1 2015 8

Number of Products under Development for Acute Heart Failure - Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 26

Aarkstore Enterprise

Number of Products by Top 10 Targets, H1 2015 27

Number of Products by Stage and Top 10 Targets, H1 2015 28

Number of Products by Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Top 10 Routes of Administration, H1 2015 31

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32

Number of Products by Top 10 Molecule Types, H1 2015 33

Number of Products by Stage and Top 10 Molecule Types, H1 2015 34

Related Market Research reports:





















Ocular Hypertension - Pipeline Review, H1 2015

Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H1 2015

Actinic (Solar) Keratosis - Pipeline Review, H1 2015

Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2015

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H1 2015

Myocardial Ischemia - Pipeline Review, H1 2015

Thalassemia - Pipeline Review, H1 2015

Encephalomyelitis - Pipeline Review, H1 2015

T-Cell Leukemia - Pipeline Review, H1 2015

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2015

About Aarkstore Enterprise

Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.

Aarkstore Enterprise

Contact Details:

Aarkstore Enterprise Phone: [phone] Email:[e-mail] Our Website:http://www.aarkstore.com Our Blog :http://www.aarkstore.com/blog/ Latest News :http://www.aarkstore.com/news Facebook:https://www.facebook.com/aarkstoredotcom